Cohort of Peripheral T Cell Lymphoma

• Conditions: Lymphoma, T-Cell, Peripheral; Febrile Neutropenia

• Registration Number: NCT02364466
• Lead Sponsor: Korea Cancer Center Hospital

Brief Summary

Prospective, observational cohort study of peripheral T cell lymphoma. Purpose is to investigate the complication including febrile neutropenia in the era of pegylated G-CSF prophylaxis.

Detailed Description

Prospective evaluation of frequencies of febrile neutropenia or infectious complications in a homogeneous population of patients with peripheral T cell lymphoma

Study Timeline

• Study Start: 2015-01
• Status Verified: 2015-02
• Study First Submitted: 2015-02-02
• Study First Submitted QC: 2015-02-10
• Last Update Submitted: 2015-02-10
• Study First Posted: 2015-02-18
• Last Update Posted: 2015-02-18
• Primary Completion: 2019-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Treatment naive peripheral T cell lymphoma

   Subtypes are as followings:

   Anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma Peripheral T cell lymphoma-NOS Enteropathy-associated T cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma

2. Scheduled to receive chemotherapy of curative intent

3. 19 years old or over

4. Expected survival is more than 6 months

5. Informed consent

Exclusion Criteria

1. Other histology than those described above

   • Extranodal NK/T cell lymphoma
   • Other than peripheral T cell lymphoma

2. Other combined malignancy

3. Previous history of chemotherapy or radiation therapy

4. No informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Febrile neutropenia	2 years after the last enrollment	Incidence and severity of febrile neutropenia

Secondary Outcome Measures

Name	Time	Method
Infectious complication	2 years after the last enrollment	incidence, severity, microbiology of infection

Trial Locations

Locations (18)

Dankook University Hospital; 🇰🇷 Cheonan, Korea, Republic of

Yeungnam University Hospital; 🇰🇷 Daegu, Korea, Republic of

Keimyung University Dongsan Hospital; 🇰🇷 Daegu, Korea, Republic of

Inje University Ilsan Paik Hospital; 🇰🇷 Ilsan, Korea, Republic of

Hanyang University Guri Hospital; 🇰🇷 Guri, Korea, Republic of

Kosin Universithy Gospel Hospital; 🇰🇷 Pusan, Korea, Republic of

National Health and Insurance Service Ilsan Hospital; 🇰🇷 Ilsan, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Pusan National University Hospital; 🇰🇷 Pusan, Korea, Republic of

Korea Cancer Center Hospital; 🇰🇷 Seoul, Korea, Republic of

Hallym University Hospital; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Soonchunhyang University Hospital; 🇰🇷 Seoul, Korea, Republic of

Ulsan University Hospital; 🇰🇷 Ulsan, Korea, Republic of

Ajou University Hospital; 🇰🇷 Suwon, Korea, Republic of

Choong Ang University Hospital; 🇰🇷 Seoul, Korea, Republic of

Hanyang University Hospital; 🇰🇷 Seoul, Korea, Republic of